Non-Muscle Invasive Bladder Cancer (NMIBC) Emerging Therapy and TPP Insights

Thelansis’s “Non-Muscle Invasive Bladder Cancer (NMIBC) Emerging Therapy, with Unmet Needs and TPP Insights Report – 2025″ provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Non-Muscle Invasive Bladder Cancer (NMIBC) Overview

Non‑muscle invasive bladder cancer (NMIBC) accounts for about 70–80% of all bladder cancer cases and includes three main categories: Ta tumors confined to the urothelium, which represent the majority; T1 tumors invading the lamina propria; and carcinoma in situ (CIS), a flat high‑grade lesion with aggressive potential. Management of NMIBC is based on complete transurethral resection of the bladder tumor (TURBT) followed by risk‑adapted intravesical therapy to reduce recurrence and progression. Intravesical chemotherapy agents such as mitomycin C, epirubicin, thiotepa, gemcitabine, and doxorubicin are commonly used, particularly in low‑risk disease, while Bacillus Calmette–Guérin (BCG) remains the most effective intravesical agent for intermediate‑ and high‑risk NMIBC, uniquely proven to delay or prevent progression to muscle‑invasive bladder cancer. Despite its generally favorable prognosis compared to muscle‑invasive disease, NMIBC requires vigilant surveillance and tailored therapy due to its high recurrence rates and variable risk of progression.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs

*Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
  • Pipeline analysis
  • Target patients for emerging therapies
  • Key companies
  • Key mechanism of actions
  • Launch date estimates, etc.
• Clinical trial landscape analysis
  • Target patient segments
  • Trial endpoints
  • Trial design
  • Recruitment criteria, etc.
• Unmet Needs and Opportunities
  • Performance of key current therapies
  • Top areas of unmet needs
  • Opportunity sizing for key unmet needs
• Target Product Profiles
  • Attributes and levels
  • Physician likelihood of prescribing
  • Expected patient shares
• KOL insights on key emerging therapies
  • Level of awareness
  • Expected use / line of therapy
  • Extent to fulfil key unmet needs
  • KOL quotes

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk,etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)